Enduring Clinical Remission in Refractory Celiac Disease Type II With Tofacitinib: An Open-Label Clinical Study

被引：5
|
作者：
Dieckman, Tessa [1 ,2 ]
Schumann, Michael [3 ]
Beaumont, Hanneke [2 ]
Bontkes, Hetty j. [4 ]
Koning, Frits [1 ]
Bouma, Gerd [2 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands
[2] Vrije Univ Amsterdam Amsterdam Gastroenterol Endoc, Dept Gastroenterol & Hepatol, Amsterdam UMC, Amsterdam, Netherlands
[3] Charite Univ Med Berlin, Div Gastroenterol Infect Dis & Rheumatol, Campus Benjamin Franklin, Berlin, Germany
[4] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam UMC locat, Lab Specialized Diagnost & Res,Dept Lab Med,Med Im, Amsterdam, Netherlands
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 22卷 / 11期
关键词：
BUDESONIDE;
D O I：
10.1016/j.cgh.2024.05.022
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2334 / 2336
页数：3
相关论文
共 50 条
  • [31] An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
    Salles, Gilles A.
    Gopal, Ajay K.
    Martin, Peter
    Marcus, Robert
    Hess, Georg
    Zinzani, Pier Luigi
    Ahmadi, Tahamtan
    Zhuang, Sen Hong
    Levy, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study
    Berkovich, Regina R.
    Sokolov, Alexey Y.
    Togasaki, Daniel M.
    Yakupova, Aida A.
    Cesar, Paul-Henry
    Sahai-Srivastava, Soma
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (02) : 64 - 69
  • [33] Open-label study of hemin for acute porphyria: Clinical practice implications
    Anderson, Karl E.
    Collins, Stephen
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 (09): : 801.e19 - 801.e24
  • [34] Open-label clinical trial of anakinra in mucopolysaccharidosis type III: Interim analysis
    Polgreen, Lynda E.
    Chen, Agnes
    O'Neill, Cara
    Luzzi, Anna
    Iacovino, Michelina
    Eisengart, Julie
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S87 - S88
  • [35] Clinical efficacy of treatment with Infliximab in a German multicenter, prospective, open-label trial in refractory Crohn's disease.
    Schreiber, S
    Kuehbacher, T
    Mascheretti, S
    Hommel, E
    Pohl, C
    Kruis, W
    Andus, T
    Lochs, H
    Fleig, W
    Thriene, W
    GASTROENTEROLOGY, 2000, 118 (04) : A568 - A568
  • [36] CLINICAL OUTCOMES OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB MONOTHERAPY IN THE OPEN-LABEL LONG-TERM EXTENSION
    Fleischmann, R.
    Wollenhaupt, J.
    Wang, L.
    Maniccia, A.
    Kwok, K.
    Takiya, L.
    van Vollenhoven, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 259 - 260
  • [37] Argatroban in the management of heparin-induced thrombocytopenia type II: an open-label, multicenter clinical trial in France
    Tardy, B.
    Nguyen, P.
    Thiranos, J-C
    Morange, P-E
    Andreani, C. B.
    Gruel, Y.
    Morel, J.
    Wynckel, A.
    Grunebaum, L.
    Villacorta-Torres, J.
    Grosjean, S.
    De Maistre, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 604 - 604
  • [38] An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
    Jabbari, A.
    Cerise, J.
    Chen, J. C.
    Sansaricq, F.
    Clynes, R.
    Christiano, A. M.
    Mackay-Wiggan, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S56 - S56
  • [39] Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study
    Singh, A. D. M.
    Midha, V.
    Mahajan, R.
    Kaur, K.
    Singh, D.
    Sood, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I111 - I111
  • [40] Maintenance of Remission With Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis From an Open-Label, Long-Term Extension Study
    Colombel, Jean-Frederic
    Reinisch, Walter
    Osterman, Mark T.
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Zhang, Haiying
    Lawendy, Nervin
    Friedman, Gary S.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S389 - S390
12345